--- title: "Revelation grants CEO and CFO restricted stock tied to market value" url: "https://aibio.space/news/revelation-grants-ceo-cfo-restricted-stock-tied-market-value/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-17" section: "Company Updates" tickers: "NASDAQ:REVB" source: "https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/revb-20260817.htm" summary: "James Rolke and Chester Zygmont each received restricted stock awards that vest in four tranches tied to market capitalization milestones of $30 million to" --- By the aibio.space news desk. Sources - [Revelation Biosciences, Inc. 8-K (2026-08-19)](https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/revb-20260817.htm) - [Revelation Biosciences, Inc. 10-K (2026-02-26): business](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/revb-20251231.htm) - [Revelation Biosciences, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1810560/000119312526076552/) [REVB](https://aibio.space/companies/revelation-biosciences/) 2026-08-17 # Revelation grants CEO and CFO restricted stock tied to market value Tickers [REVB](https://aibio.space/companies/revelation-biosciences/) James Rolke and Chester Zygmont each received restricted stock awards that vest in four tranches tied to market capitalization milestones of $30 million to $120 million. ## Key facts - **Company**: Revelation Biosciences, Inc. (NASDAQ: REVB) - **News type**: Company Updates - **Primary source**: [Revelation Biosciences, Inc. 8-K (2026-08-19)](https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/revb-20260817.htm) *Scientists in a laboratory. Photo: Esculab, CC0, via Wikimedia Commons. The picture shows the field, not the companies named.* On August 17, 2026, the Compensation Committee of the Board of Directors of Revelation Biosciences, Inc. approved grants of restricted shares of the company's common stock to its executives. The grants were made effective the same day under the company's Amended and Restated 2021 Equity Incentive Plan. The company disclosed the grants in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/revb-20260817.htm) that lists the executives as James Rolke, Chief Executive Officer, and Chester S. Zygmont, III, Chief Financial Officer. ## The awards Mr. Rolke received a Restricted Stock Award covering 208,076 shares of common stock. Mr. Zygmont received an award covering 208,073 shares. Each award vests in four equal tranches of 25%, subject to the executive's continued service with the company or one of its subsidiaries through the applicable vesting date. The first tranche vests upon the earlier of the company reaching a market capitalization of $30 million for 20 consecutive trading days or the second anniversary of the grant date. The second tranche vests upon the earlier of a $60 million market capitalization for 20 consecutive trading days or the second anniversary. The third tranche vests upon the earlier of $90 million for 20 consecutive trading days or the fourth anniversary. The fourth tranche vests upon the earlier of $120 million for 20 consecutive trading days or the fourth anniversary. Each tranche also vests on a fixed anniversary, so the awards pay out by time alone even if no market value target is reached. The new shares add to the share count. Market capitalization is calculated by multiplying the closing sale price of the common stock on the principal exchange by the number of shares outstanding at the close of business on that trading day. ## Change of control and termination The awards become fully vested immediately before, and contingent upon, the completion of a change in control as defined in the 2021 Plan, unless an individual agreement provides otherwise. If an executive's service ends because of death, termination by the company without Cause, or resignation for Good Reason as defined in the award agreement, the award becomes fully vested and nonforfeitable. Unvested shares are forfeited if service ends for any other reason, including termination for Cause, Disability or Retirement, as those terms are defined in the 2021 Plan. The form of Restricted Stock Award Agreement is filed as Exhibit 10.1 to the 8-K. ## The company Revelation describes itself as a clinical-stage life science company focused on rebalancing inflammation with its proprietary formulation, Gemini. Gemini is a formulation of phosphorylated hexaacyl disaccharide (PHAD), a Toll-like receptor 4 agonist. Its lead programs are GEM-AKI, evaluated as an acute treatment for acute kidney injury, and GEM-CKD, for chronic kidney disease. The company has used several reverse stock splits, which signal a long slide in its share price, and its lead programs have no clinical results in these sources. Its annual report lists a 1-for-30 split effective January 25, 2024, a 1-for-16 split effective January 28, 2025, a 1-for-3 split effective July 7, 2025, and a 1-for-4 split effective January 28, 2026. ## Financial position The annual report, filed February 26, 2026, shows research and development expense of $4.1 million for 2025, compared with $3.5 million for 2024. The net loss was $8.9 million for 2025, compared with $15.0 million for 2024. Cash used in operations was $8.3 million in 2025, compared with $18.3 million in 2024. Year-end 2024 cash and cash equivalents were $6.5 million. The company's quarterly report filed August 6, 2026 reported cash and cash equivalents of $11.5 million at June 30, 2026. The year-end 2025 figure in that report was $10.7 million. The net loss was of $8.9 million in 2025 and cash used in operations of $8.3 million. ## What comes next The award agreements describe the vesting conditions above, and the next vesting dates depend on the market capitalization milestones or on the second and fourth anniversaries of the August 17, 2026 grant date. The filing does not set a date for any further grants. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story REVB Revelation Biosciences, Inc. NASDAQ ยท United States Open the starter desk ## More in Company Updates Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 Company Updates ### [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Oct 29, 2026 Company Updates ### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Oct 29, 2026 --- Source page: https://aibio.space/news/revelation-grants-ceo-cfo-restricted-stock-tied-market-value/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Revelation grants CEO and CFO restricted stock tied to market value", 2026-08-17, https://aibio.space/news/revelation-grants-ceo-cfo-restricted-stock-tied-market-value/